The historical rank and industry rank for Rekah Pharmaceutical Prod's Net Margin % or its related term are showing as below:
XTAE:REKA'
s Net Margin % Range Over the Past 10 Years
Min: -12.52 Med: 0.62 Max: 4.07
Current: -6.1
XTAE:REKA's Net Margin % is ranked worse than 73.87% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs XTAE:REKA: -6.10
Rekah Pharmaceutical Prod (XTAE:REKA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Rekah Pharmaceutical Prod Net Margin % Related Terms
Rekah Pharmaceutical Prod Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:REKA vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rekah Pharmaceutical Prod Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's Net Margin % distribution charts can be found below:
* The bar in red indicates where Rekah Pharmaceutical Prod's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rekah Pharmaceutical Prod (XTAE:REKA) has a Net Margin % of -3.63% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Rekah Pharmaceutical Prod and its competitors. According to the industry distribution chart, Rekah Pharmaceutical Prod ranks #704 out of 953 companies in the Drug Manufacturers industry, placing it in the top 73.9%.
Is Rekah Pharmaceutical Prod's Net Margin % too high?
Rekah Pharmaceutical Prod's current Net Margin % is -3.63%. Based on the distribution chart, Rekah Pharmaceutical Prod ranks #704 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rekah Pharmaceutical Prod has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rekah Pharmaceutical Prod's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rekah Pharmaceutical Prod ranks #704 out of 953 companies for Net Margin %. This places Rekah Pharmaceutical Prod in the lower half of its industry. The industry median Net Margin % is 5.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Rekah Pharmaceutical Prod and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rekah Pharmaceutical Prod's current Net Margin % is -3.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rekah Pharmaceutical Prod stock overvalued right now?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod (XTAE:REKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪13.05, compared to a current price of ₪10.62 — trading 18.6% below its estimated fair value. The current Net Margin % is -3.63%. Rekah Pharmaceutical Prod's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Rekah Pharmaceutical Prod (XTAE:REKA), the current Net Margin % is -3.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued.
The current stock price of ₪10.62 is trading 18.6% below its estimated GF Value™ of ₪13.05.
GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.
Key valuation signals for XTAE:REKA:
Net Margin %: -3.63%
GF Value™: ₪13.05 vs. price of ₪10.62 (18.6% below fair value)
No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score
Get the complete analysis for XTAE:REKA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:REKA has been successfully added to your 
